<DOC>
	<DOC>NCT02228785</DOC>
	<brief_summary>This study was designed to investigate the safety and tolerance of three doses (100µg, 200µg, 500µg) of G17DT for the treatment of patients with colorectal cancer.</brief_summary>
	<brief_title>A Study of the Safety and Tolerance of Three Doses of G17DT in Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Gastrins</mesh_term>
	<criteria>Patients aged 18 years or over with histologically verified adenocarcinoma of colon or rectum. Recurrent of metastatic disease not amenable to curative surgery and/or radiotherapy. Life expectancy greater than 3 months. Karnofsky Index Score greater than or equal to 50%. Written informed consent obtained. Neoplastic lesions other than colorectal cancer (except treated basal cell carcinoma of the skin or cancer of the uterine cervix, through Stage I. Acute intercurrent illness. Patient considered to be a medical risk because of nonmalignant systemic disease or grossly abnormal laboratory results. Patients who had received any other anticancer therapy within 3 months. Factor liable to alter the serum gastrin concentration or affect intragastric acidity, for instance concomitant therapy with H2 receptor antagonist drugs, proton pump inhibitors, or previous gastric surgery. Patients immunologically compromised including those on corticosteroid therapy. Women of childbearing age. Positive immediate hypersensitivity reaction to skin testing with study medication. Patients unable to complete the diary book Haematogical Status Haemoglobin count less than 10g/dL White Blood Cell count less than 4.0 x 10^9/L Platelet count less than 100 x 10^9/L</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>